Clinical trial · Interventional
Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
The Effectiveness and Safety of Treating Operable Breast Cancer by the Adjuvant Therapy of Zoledronic Acid and Aromatase Inhibitors and/or Ovarian Function Inhibition
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Select patients of primary breast cancer whose hormone receptor is positive and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with zoledronic acid 4mg intravenous infusion every six months until the end of the aromatase treatment. Assess the disease-free survival; overall survival; combination of security, as well as the situation of bone loss.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Zoledronic Acid and Aromatase Inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Zoledronic Acid and Aromatase Inhibitors
- description
- Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy
- interventionNames
- Drug: Zoledronic Acid and Aromatase Inhibitors
Primary outcomes (1)
- measure
- therapeutic assessment
- timeFrame
- 6 months
- description
- therapeutic assessment
Secondary outcomes (1)
- measure
- Adverse reactions and disease-free survival
- timeFrame
- 2 years
- description
- Adverse reactions and disease-free survival
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: 1. Karnofsky≥70 2. Provision of informed consent 3. Pathological confirmation of breast cancer 4. Hormone receptor-positive and accept aromatase inhibitors for adjuvant endocrine therapy 5. Not previously received treatment with bisphosphonate 6. Laboratory criteria: PLT≥100\*109/L WBC≥4000/mm3 HGB≥10g/dl GOT,GPT,ALP≤2\*ULN TBIL,DBIL,CCr≤1.5\*ULN 7. Surgery , radiotherapy and chemotherapy has finished Exclusion Criteria: 1. Pregnant of lactation woman 2. History of organ transplantation 3. With mental disease 4. With severe infection or active gastrointestinal ulcers 5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes 6. Disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ) 7. With heart disease 8. Experimental drug allergy
References
Publications (0)
Data not yet available